The morphological changes in
Introduction
Tumor necrosis factor-a (TNF-a) is a cytokine with activity against a number of tumors including malig nant gliomas of the brain .1,14,11) Malignant glioma cells as well as the tumor blood vessels may be the tar gets.4,8,19) TNF-a modulates procoagulant activity and expression of adhesion molecules in cultured en dothelial cells .3,20) However, the in vivo effects on vas cular endothelial cells are not well documented. Previously, the effects of TNF-a on cultured vascular endothelial cells were extensively studied, 3,12,17,20) but the effects on the tumor blood vessels in vivo are little known.'"') Intraluminal thrombus formation and leukocyte accumulation have been studied, but not the morphological changes of vascular endothelial cells.
The present study investigated the effects of TNF a on the endothelial cells of tumor blood vessels and the distribution of TNF-a binding sites in a rat malig nant glioma model.
Materials and Methods
Female Wistar rats weighing approximately 200 g were anesthetized with ketamine hydrochloride (80 mg/kg, i.p.). Under aseptic conditions, 1 x 105 C6 glioma cells suspended in 10,u1 of Ham's F10 medi um were injected stereotactically into the right cau date-putamen. ' Fourteen days after tumor cell inocu lation, 5 x 10'U of human natural-type TNF-a (Mochida Pharmaceutical Co., Ltd., Tokyo; specific activity 2 x 106 U/mg protein) was infused into the internal carotid artery. Rats were sacrificed 3 or 24 hours after administration of TNF-a (both n = 4). Other rats bearing C6 glioma without any treatment were also sacrificed (n = 4). The brain was removed, immediately frozen in isopropyl alcohol, and stored at 80°C. Immunohistochemical staining for factor VIII related antigen (FVIIIRAg) was carried out as de scribed previously.',") Briefly, cryostat sections of 6 gm-thickness were fixed in 4% paraformaldehyde and incubated in Tris-HCl buffer containing 0.3% hydrogen peroxide, then washed. Staining used the avidin-biotin-peroxidase complex (ABC) method (Vectastain ABC kit®; Vector, Burlingame, Cal., U.S.A.). Nonspecific binding was blocked by tissue conditioner (Biomeda, Foster, Cal., U.S.A.). Sec tions were incubated in prediluted goat anti-FVIII RAg antibody (Biomeda) overnight at 4°C, in biotinylated anti-goat immunoglobulin G (Biomeda) for 30 minutes, and reacted with ABC complex for 30 minutes, then 3,3-diaminobenzidine tetra hydrochloride and counterstained in hematoxylin. Control sections were incubated in normal goat se rum instead of the primary antibody. The nuclear size of the vascular endothelial cell was measured with an image processing system (NIH Image 1.47).') At least 50 endothelial cells were analyzed in the five square regions of interest selected arbitrarily within the tumor and in the brain remote from the tumor (Fig. 1) . The data were expressed as mean ± SD (,um'). Statistical differences were analyzed by the Mann-Whitney U test.
The distribution of TNF-a binding sites was studied using a method modified from the in vitro autoradiographic receptor mapping technique.") Cryostat sections of 6,um-thickness were fixed in 1 % paraformaldehyde in phosphate-buffered saline (PBS) for 5 minutes, washed in PBS, pH 7.4, and in cubated with biotinylated TNF-a (TNF-a-biotin, 300 ng/ml; Boehringer Mannheim, Mannheim, Ger many) overnight at 4°C. The sections were washed in PBS, and reacted with streptoavidin-alkaline phos phatase (Histofine®; Nichirei Corp., Tokyo) for 1 hour at room temperature. After washing, these sec tions were incubated with Vector Red® (Vector) for 20 minutes and counterstained with hematoxylin. In cubation of control sections used unlabeled TNF-a (Boehringer Mannheim) instead of TNF-a-biotin at the same protein concentration.
Competitive inhibi tion was checked by adding an excess amount of TNF-a (20,ug/ml). 
Results
Vascular endothelial cells were readily identified by the positive immunoreaction to FVIIIRAg. In the un treated rats, the thickness of the vascular endotheli um within the tumor was similar to that in the brain remote to the tumor. However, endothelial cells within the tumor had increased in thickness as early as 3 hours after administration of TNF-a, and con tinued to increase in thickness at 24 hours after the treatment (Fig. 2) . The thickened cells contained both cytoplasm and cell nuclei with increased size. The vascular endothelial cells in the brain remote to the tumor were not affected. The light microscopic morphologies of the tumor cells or of the neuronal and glial cells were not affected during the present ex perimental study.
The morphometric analysis demonstrated that the sizes of the vascular endothelial cell nuclei within the tumor were similar to those in the brain remote to the tumor in the untreated rats (17.3 ± 0.8 and 16.2 ± 1.1 ,um2, respectively), but were significantly (p < 0.05) increased in size at both 3 and 24 hours after ad ministration of TNF-a (28.1 ± 1.4 and 36.0 ± 1.9 µm2, respectively). The sizes of the endothelial cell nuclei in the brain remote to the tumor remained un changed (16.4 ± 1.0 and 17.6 ± 0.8 ,um2 at 3 and 24 hours after treatment, respectively). The receptor binding study demonstrated that the endothelial cells of almost all the blood vessels within the tumor were positive for TNF-a binding sites, but those in the brain remote to tumor were totally negative (Fig. 3) . The tumor cells as well as the neuronal and glial cells of the brain were also negative for TNF-a binding sites.
Discussion
The present study showed that TNF-a caused in creases in the size of both the endothelial cells and their nuclei in the blood vessels within the tumor. Swelling of endothelial cells is a rather nonspecific finding related to various kinds of cytotoxic events such as ischemia, reperfusion, and radiation. 6,9,16) The morphological changes observed in this study may also be related to the cytotoxic process after ex posure to TNF-a. Previous studies using the ex The present study used a TNF-a dose of 5 x 103 U/animal (approximately 1.7 x 105 U/m2), which is comparable to those used clinically for intracarotid administration in patients with malignant gliomas (1-2 x 105 U/m2).22> In this trial, the peritumoral ede ma was increased in several patients.22) Since en dothelial cell damage leads to the increased permeability and aggravation of vasogenic edema,") the increase in periturnoral edema in this trial could be related to the effect of TNF-a on the tumor blood vessels. The presence study focused on the effect of TNF-a on the endothelial cells of the tumor blood vessels, but the direct effect on the tumor cells is also of in terest. In the present study, no direct effect on the tumor cells was expected since C6 glioma cells were negative for TNF-a binding sites. However, some hu man glioma-derived cell lines demonstrated an in creased number of TNF-a receptors,18) so TNF-a may affect both the blood vessels and the tumor cells.
Malignant gliomas are difficult to control using all measures currently available, including surgery, radiotherapy, and chemotherapy.
The selective cyto toxicity of TNF-a on the tumor blood vessels en courages application of this cytokine as an adjuvant treatment in managing this incurable malignancy. They have demonstrated that even in a tumor such as C6 which has no TNF-a bind ing sites, the vessels induced by the tumor not only contain such sites but express them at a substantially higher level than normal brain. Moreover these tumor vessels demonstrate changes in the endothelial cells in response to infused TNF-a. Both the ther apeutic effects and unwanted side-effects of this drug may be explained at least in part by these findings. Not mentioned in the article but also of significance is that this provides evidence that may prove useful for using TNF-a and its receptors as a specific target ing strategy coupled with other agents for gene trans fer, viral therapy, toxin-associated therapies, and/or angiogenesis inhibition.
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The article by Isaka et al. effectively demonstrates the morphological changes of vascular endothelial cells in the tumor following intra-arterial administra tion of TNF-a in glioma-bearing mice. The altera tion observed by the immunohistochemistry using factor VIII-related antigen consisted of increase in size of both endothelial cells and their nuclei that is consistent to alteration seen in ischemia or irradia tion. The alteration was observed selectively in the tumor as early as 3 hours after administration of TNF-a and remained so at 24 hours after administra tion. No alteration was seen in blood vessels of the normal brain infused with TNF-a. Various reports have demonstrated that TNF has cytotoxic effects against vascular endothelial cells in vitro and suggest ed that reactions affecting the tumor vasculature may be involved in the overall antitumor mechanism of TNF in addition to its direct effect against tumor cells. In vivo, TNF was shown to induce disruption of blood brain barrier, hemorrhage, thrombus for mation, and circulation blockage in the tumor vas culature. This study has provided clear and direct evi dence of toxic effects by TNF-a on vascular en dothelial cells in the tumor in vivo. The authors also studied binding sites of TNF-a in the blood vessels by the autoradiographic receptor mapping technique and found that TNF-a binding sites were selectively distributed in vascular endothelial cells in the tumor. This is also the new information that might explain the previous and present observations that in travenous or intra-arterial TNF exerts a strong cyto toxic effect on newly formed tumor vasculature but no toxic effects on normal blood vessels. The authors have provided important informations concerning the effect of TNF-a in the treatment of gliomas.
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